 Moderna Inc, the biotech pioneering messenger RNA mRNA therapeutics and vaccines, said it has struck a deal to buy Japan-based OriCiro Genomics for US85 million to boost its manufacturing capabilities. With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing, said Stéphane Bancel, the CEO of Moderna, in a statement. 